Cargando…

Severity-Adjusted Probability of Being Cost Effective

BACKGROUND: In the context of priority setting, a differential cost-effectiveness threshold can be used to reflect a higher societal willingness to pay for quality-adjusted life-year gains in the worse off. However, uncertainty in the estimate of severity can lead to problems when evaluating the out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Versteegh, Matthijs M., Ramos, Isaac Corro, Buyukkaramikli, Nasuh C., Ansaripour, Amir, Reckers-Droog, Vivian T., Brouwer, Werner B. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830403/ https://www.ncbi.nlm.nih.gov/pubmed/31134467 http://dx.doi.org/10.1007/s40273-019-00810-8

Ejemplares similares

Who should receive treatment? An empirical enquiry into the relationship between societal views and preferences concerning healthcare priority setting
por: Reckers-Droog, Vivian, et al.
Publicado: (2018)

Presentation and validation of the Abbreviated Self Completion Teen-Addiction Severity Index (ASC T-ASI): A preference-based measure for use in health-economic evaluations
por: Reckers-Droog, Vivian, et al.
Publicado: (2020)

The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice
por: Wouterse, Bram, et al.
Publicado: (2023)

Distributional consequences of including survivor costs in economic evaluations
por: Kellerborg, Klas, et al.
Publicado: (2021)

Coverage with evidence development for medical devices in Europe: Can practice meet theory?
por: Drummond, Michael, et al.
Publicado: (2022)

Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
por: Federici, Carlo, et al.
Publicado: (2021)

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal
por: Thielen, Frederick W., et al.
Publicado: (2018)

Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries
por: Kovács, Sandor, et al.
Publicado: (2022)

A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending
por: van Baal, Pieter, et al.
Publicado: (2018)

Viewpoints among experts and the public in the Netherlands on including a lifestyle criterion in the healthcare priority setting
por: Dieteren, Charlotte M., et al.
Publicado: (2021)

Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
por: Versteegh, Matthijs
Publicado: (2016)

Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states
por: Lipman, S. A., et al.
Publicado: (2021)

Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE)
por: Wester, Valérie, et al.
Publicado: (2020)

Value of information analysis in telehealth for chronic heart failure management
por: Grustam, Andrija S., et al.
Publicado: (2019)

The value of health—Empirical issues when estimating the monetary value of a quality‐adjusted life year based on well‐being data
por: Himmler, Sebastian, et al.
Publicado: (2021)

On the Probable Sensations of the Head, after Being Severed from the Body
Publicado: (1799)

TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2019)

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(®) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy
por: Selya-Hammer, Carl, et al.
Publicado: (2016)

Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries
por: Mokri, Hamraz, et al.
Publicado: (2022)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis
por: Javanbakht, Mehdi, et al.
Publicado: (2022)

The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios
por: Franken, Margreet G, et al.
Publicado: (2018)

Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis
por: Albuquerque de Almeida, Fernando, et al.
Publicado: (2022)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

An Adjusted Probability Method for the Identification of Sociometric Status in Classrooms
por: García Bacete, Francisco J., et al.
Publicado: (2017)

The probability of cost-effectiveness
por: O'Hagan, Anthony, et al.
Publicado: (2002)

The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review
por: Cacciatore, Pasquale, et al.
Publicado: (2020)

Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study
por: van Hezik-Wester, Valérie, et al.
Publicado: (2022)

Estimating the monetary value of health and capability well-being applying the well-being valuation approach
por: Himmler, Sebastian, et al.
Publicado: (2020)

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2018)

Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium
por: Postma, Maarten J., et al.
Publicado: (2023)

Reply to Standaert, B. Comment on “Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium”
por: Postma, Maarten J., et al.
Publicado: (2023)

Reference‐dependent age weighting of quality‐adjusted life years
por: Attema, Arthur E., et al.
Publicado: (2022)

Analyzing histone ChIP-seq data with a bin-based probability of being signal
por: Hecht, Vivian, et al.
Publicado: (2023)

Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity
por: Guedes, Ricardo Augusto Paletta, et al.
Publicado: (2016)

Anticipatory Adjustments to Being Picked Up in Infancy
por: Reddy, Vasudevi, et al.
Publicado: (2013)

A short note on measuring subjective life expectancy: survival probabilities versus point estimates
por: Rappange, David R., et al.
Publicado: (2016)

Coping with Everyday Stress, Assessment and Relationships, Psychological Adjustment, Well-Being and Socioemotional Adjustment
por: Rodríguez, Francisco Manuel Morales
Publicado: (2022)

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
por: Ansaripour, Amir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8hlo84705orfufcmk3bhrr4a6q